1.0 Purpose
This protocol describes the design and execution of accelerated and long-term stability studies for lyophilized synthetic peptide lots. The objective is to generate time-dependent purity, appearance, and moisture data sufficient to assign a shelf life and storage statement for each compound.
Accelerated stability conditions allow extrapolation of long-term behavior using Arrhenius kinetics. ICH Q1A(R2) defines the standard conditions applicable to drug substances; this note applies equivalent methodology to research-grade lyophilized peptides [1].
2.0 Storage Conditions
Three storage conditions are maintained in parallel from the date of lot release (T = 0). Samples are housed in sealed Type I borosilicate glass vials (identical to commercial packaging) with bromobutyl rubber stoppers, nitrogen headspace, and aluminum crimp seals.
| Condition | Temperature | Relative Humidity | Duration | ICH Designation |
|---|---|---|---|---|
| Long-term | 25°C ± 2°C | 60% RH ± 5% | 24 months (minimum) | Zone II long-term |
| Intermediate | 30°C ± 2°C | 65% RH ± 5% | 12 months | Zone II intermediate |
| Accelerated | 40°C ± 2°C | 75% RH ± 5% | 6 months | Zone II accelerated |
| Proposed storage (reference) | −20°C ± 5°C | Not controlled (sealed) | Continuous; concurrent with above | Reference condition |
Temperature and humidity within each chamber are recorded continuously by a calibrated datalogger (minimum 15-minute intervals). Deviation from specified conditions for more than 24 continuous hours constitutes an out-of-specification (OOS) event requiring documentation.
3.0 Sampling Schedule
Samples are withdrawn at each time point from the relevant storage chambers and analyzed within 5 business days of withdrawal. Each time-point pull consists of three independently sealed vials per condition (n = 3). Vials are not returned to storage after analysis.
| Time Point | Long-Term (25°C/60%) | Intermediate (30°C/65%) | Accelerated (40°C/75%) |
|---|---|---|---|
| T = 0 (initial) | ✓ | ✓ | ✓ |
| 1 month | — | — | ✓ |
| 2 months | — | — | ✓ |
| 3 months | ✓ | ✓ | ✓ |
| 6 months | ✓ | ✓ | ✓ (final) |
| 9 months | ✓ | ✓ | — |
| 12 months | ✓ | ✓ (final) | — |
| 18 months | ✓ | — | — |
| 24 months | ✓ (final) | — | — |
4.0 Assay Methods
Each vial withdrawn at a given time point is tested for all attributes below. Tests are performed in the order listed; appearance is always recorded first on the intact closed vial before opening.
| Test | Method Reference | Performed On |
|---|---|---|
| Appearance (lyophilized cake) | Visual inspection, standardized light box, daylight D65 equivalent | Closed vial; before opening |
| HPLC Purity | NX-MN-001 (RP-HPLC, C18, UV 220 nm) | Reconstituted solution; per method |
| Water content (Karl Fischer) | USP <921> coulometric KF titration | Lyophilized powder; vial opened in low-humidity environment |
| Identity (ESI-MS) | ESI-MS, positive mode; initial and 24-month points only | Reconstituted solution |
| pH (reconstituted) | USP <791> potentiometric; micro-pH electrode | 1 mg/mL solution in WFI |
5.0 Acceptance Criteria
Acceptance criteria are defined at T = 0 based on the initial lot release specification. A stability failure is declared when any result falls outside the criterion at any time point.
| Attribute | Criterion (All Time Points) | Criterion (Initial T=0) |
|---|---|---|
| Appearance | White to off-white cake; no collapse, discoloration, or visible particulates upon reconstitution | White to off-white powder |
| HPLC purity (main peak) | ≥95.0% (area percent) | ≥98.0% (area percent) |
| Individual impurity | ≤2.0% (area percent, any single peak) | ≤1.0% |
| Water content | ≤8.0% w/w | ≤6.0% w/w |
| pH (reconstituted) | 4.0–7.0 (peptide-dependent; set per compound specification) | 4.0–7.0 |
| Identity | Confirmed at T=0 and T=24 months only; mass within ±0.5 Da of theoretical | Required for lot release |
Data trending is reviewed at each time point by the quality coordinator. A trend toward a criterion boundary (defined as an individual result within 10% of the limit) initiates a trend review.
6.0 Shelf Life Assignment
Shelf life is assigned as the time interval during which all stability attributes remain within acceptance criteria under the proposed storage condition (−20°C). For initial lot release, a tentative shelf life of 24 months is assigned based on available accelerated data and literature precedent for analogous lyophilized peptides.
The shelf life is confirmed, extended, or shortened following review of real-time data at each scheduled time point. Extension beyond 24 months requires at least 24 months of continuous long-term stability data showing no adverse trend [2].
7.0 References
- [1] ICH Harmonised Tripartite Guideline Q1A(R2). (2003). Stability Testing of New Drug Substances and Products. International Council for Harmonisation. https://database.ich.org/sites/default/files/Q1A%28R2%29%20Guideline.pdf
- [2] ICH Harmonised Tripartite Guideline Q1E. (2004). Evaluation for Stability Data. International Council for Harmonisation. https://database.ich.org/sites/default/files/Q1E%20Guideline.pdf
- [3] United States Pharmacopeia (2024). USP <659> Packaging and Storage Requirements.
- [4] United States Pharmacopeia (2024). USP <921> Water Determination.
- [5] Bhambhani A. et al. (2012). Formulation design and process development for lyophilization of a peptide drug product. Journal of Pharmaceutical Sciences, 101(6):1988–2001. DOI:10.1002/jps.23075